Literature DB >> 33242156

The immunohistochemical expression of von Willebrand factor, T-cadherin, and Caveolin-1 is increased in kidney allograft biopsies with antibody-mediated injury.

André Costa Teixeira1,2, Fábio Távora3,4, Melissa Lou Fagundes de Deus E Silva5, Renan Martins Gomes Prado5, Ronaldo de Matos Esmeraldo6, Tainá Veras de Sandes-Freitas3,6.   

Abstract

BACKGROUND: There are only a few reports evaluating the applicability of endothelial-damage markers analysis by immunohistochemistry (IHC) in kidney allograft samples. This study analyzed the expression of Caveolin-1 (Cav), von Willebrand factor (Vwf), and T-cadherin (Cad) in kidney biopsies and their association with antibody-mediated injury.
METHODS: In this retrospective study, 114 cases with antibody-mediated changes (Banff, 2020) and 72 with interstitial fibrosis/tubular atrophy were selected. IHC for Cav, Vwf and Cad was performed and evaluated according to their qualitative expression in peritubular capillaries. The cases were grouped according to the presence of microvascular inflammation (MVI), donor-specific antibodies (DSA), C4d positivity and antibody-mediated rejection (AMR). A level of significance < 0.05 was adopted.
RESULTS: Vwf expression was associated with MVI (p < 0.001), DSA (p = 0.016), C4d (p < 0.001) and AMR (p < 0.001), and was higher in DSA+/C4d+ cases despite MVI (p < 0.001). The expression of Cad correlated with MVI (p = 0.015), C4d (p = 0.005) and AMR (p = < 0.001). Cad was more expressed in chronic AMR compared with acute/active cases (p = 0.001). Cav expression was associated with MVI (p = 0.029) and AMR (p = 0.016) and was also higher in chronic AMR (p = 0.049). A combined score of Vwf and Cad was higher in AMR when compared with C4d without rejection and IF/TA cases (p < 0.001).
CONCLUSION: Vwf, Cad and Cav expression shows association with antibody-mediated injury and may be helpful to support AMR diagnosis.

Entities:  

Keywords:  Antibody-mediated rejection; Caveolin-1; Immunohistochemistry; T-cadherin; Von willebrand factor

Year:  2020        PMID: 33242156     DOI: 10.1007/s10157-020-01994-6

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  28 in total

1.  Banff 2003 meeting report: new diagnostic insights and standards.

Authors:  Lorraine C Racusen; Philip F Halloran; Kim Solez
Journal:  Am J Transplant       Date:  2004-10       Impact factor: 8.086

2.  A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants.

Authors:  B Sis; G S Jhangri; J Riopel; J Chang; D G de Freitas; L Hidalgo; M Mengel; A Matas; P F Halloran
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

Review 3.  Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection.

Authors:  Banu Sis; Philip F Halloran
Journal:  Curr Opin Organ Transplant       Date:  2010-02       Impact factor: 2.640

4.  Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining.

Authors:  Banu Sis; Gian S Jhangri; Sakarn Bunnag; Kara Allanach; Bruce Kaplan; Philip F Halloran
Journal:  Am J Transplant       Date:  2009-07-22       Impact factor: 8.086

Review 5.  Evolving criteria for the diagnosis of antibody-mediated rejection in renal allografts.

Authors:  Mark Haas
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-05       Impact factor: 2.894

6.  The evolution of the Banff classification schema for diagnosing renal allograft rejection and its implications for clinicians.

Authors:  D M Bhowmik; A K Dinda; P Mahanta; S K Agarwal
Journal:  Indian J Nephrol       Date:  2010-01

Review 7.  Endothelial molecules decipher the mechanisms and functional pathways in antibody-mediated rejection.

Authors:  Banu Sis
Journal:  Hum Immunol       Date:  2012-07-31       Impact factor: 2.850

8.  Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.

Authors:  M Haas; B Sis; L C Racusen; K Solez; D Glotz; R B Colvin; M C R Castro; D S R David; E David-Neto; S M Bagnasco; L C Cendales; L D Cornell; A J Demetris; C B Drachenberg; C F Farver; A B Farris; I W Gibson; E Kraus; H Liapis; A Loupy; V Nickeleit; P Randhawa; E R Rodriguez; D Rush; R N Smith; C D Tan; W D Wallace; M Mengel
Journal:  Am J Transplant       Date:  2014-02       Impact factor: 8.086

9.  Antibody-mediated rejection in kidney transplantation: a review.

Authors:  Chethan Puttarajappa; Ron Shapiro; Henkie P Tan
Journal:  J Transplant       Date:  2012-04-10

10.  The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.

Authors:  M Haas; A Loupy; C Lefaucheur; C Roufosse; D Glotz; D Seron; B J Nankivell; P F Halloran; R B Colvin; Enver Akalin; N Alachkar; S Bagnasco; Y Bouatou; J U Becker; L D Cornell; J P Duong van Huyen; I W Gibson; Edward S Kraus; R B Mannon; M Naesens; V Nickeleit; P Nickerson; D L Segev; H K Singh; M Stegall; P Randhawa; L Racusen; K Solez; M Mengel
Journal:  Am J Transplant       Date:  2018-01-21       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.